[CAS NO. 56238-63-2]??Cefuroxime sodium

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [56238-63-2]

Catalog

HY-B1256

Brand

MCE

CAS

56238-63-2

DESCRIPTION [56238-63-2]

Overview

MDL	-
Molecular Weight	446.37
Molecular Formula	C16H15N4NaO8S
SMILES	O=C(C(N12)=C(COC(N)=O)CS[C@]2([H])[C@H](NC(/C(C3=CC=CO3)=N\OC)=O)C1=O)O[Na]

For research use only. We do not sell to patients.

3 Publications Citing Use of MCE

[1]Nat Commun. 2022 Mar 2;13(1):1116.
[2]J Chem Inf Model. 2021 Mar 18.
[3]Biomed Res Int. 2018 Jul 2;2018:3579832.

Summary

Cefuroxime sodium is an orally active second-generation cephalosporin antibiotic with increased stability to β-lactamase . Cefuroxime sodium has a broad spectrum activity against Gram-positive and Gram-negative bacteria ^[1] .

In Vitro

Cefuroxime sodium is highly active against S. aureus (MIC=0.25 μg/ml), regardless of whether the strains produces a penicillinase. It is against Staphylococcus aureus methicillin susceptible; S. aureus , methicillin resistant, Streptococcus pyogenes , S. pneumoniae , S. viridans , S. faecalis , and Clostridium spp with MIC values of 0.25 μg/ml, 5.9 μg/ml, 0.125 μg/ml, 0.125 μg/ml, 0.125 μg/ml, >125.0 μg/ml, and 1.2 μg/ml, respectively ^[1] .
Cefuroxime sodium (10-100 μg/ml; 2-6 hours) rapidly bactericidal, its action is comparatively slow against the strains of S. aureus , but, even so, over 99% of the initial inoculum is killed by 6 h. The gram-negative organisms are killed rapidly, and in most cases over 99% of the very large inocula are killed within 2 h; the β-lactamase-producing strains are killed as quickly as non-enzyme-producing strains ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Rabbits (weighing 2.0 to 2.5 kg) are challenged intravenously with S. aureus strain 630 (a penicillinase-producing strain), the median effective dose of Cefuroxime sodium is 3 mg/kg as a result of the protection test ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02009098	Odense University Hospital\|Region of Southern Denmark\|University of Southern Denmark\|Hvidovre University Hospital\|Hospital of South West Jutland	Postoperative Infection	October 2014	Phase 4
NCT02162134	Benazir Bhutto Hospital, Rawalpindi	Postoperative Ileus.	January 2013	Not Applicable
NCT03141476	Universit?tsklinikum Hamburg-Eppendorf	Obesity; Drug	March 1, 2017	Phase 4
NCT01138852	Attikon Hospital	Surgical Site Infections	July 2004	Phase 4
NCT00355602	University of Dundee\|Tenovus Scotland	Colitis, Ulcerative	July 2006	Not Applicable
NCT04212078	National University of Malaysia\|Santen Pharmaceutical Co., Ltd.	Endophthalmitis Postoperative	July 29, 2019	Phase 1\|Phase 2
NCT01507974	HaEmek Medical Center, Israel	Pregnancy Complications	January 16, 2012	Not Applicable
NCT02169856	Benazir Bhutto Hospital, Rawalpindi	Postoperative Nausea and Vomiting	July 2013	Not Applicable
NCT00530400	Centre Hospitalier Universitaire Vaudois\|University Hospital, Geneva\|GlaxoSmithKline	Surgical Wound Infection	April 1994	Phase 4
NCT01080963	Hannover Medical School\|Novartis	Wound Infection	November 2008	Phase 4
NCT02819570	Western Galilee Hospital-Nahariya	Premature Rupture of Membrane	November 2015	Phase 4
NCT00136344	City, University of London\|The European Society of Cataract and Refractive Surgeons(ESCRS)\|Santen Gmbh	Endophthalmitis	September 2003	Not Applicable
NCT02505581	Hospital Universitari Vall d′Hebron Research Institute	Surgical Wound Infection	May 2015	Phase 4
NCT04479657	Zhong Wang\|China Academy of Chinese Medical Sciences	Upper Respiratory Tract Infection\|Bacterial Infection\|Chinese Medicine\|Pediatric Acute Upper Respiratory Tract Infection	October 17, 2020	Early Phase 1
NCT01372371	Ganga Hospital	Infection	June 2011	Not Applicable
NCT00901628	Seoul National University Hospital	Osteoarthritis, Knee	April 2008	Phase 4
NCT00162604	Hvidovre University Hospital	Uterine Prolapse\|Cystocele\|Rectocele\|Enterocele	May 2005	Not Applicable
NCT02445859	University of Leeds	Surgical Site Infection	August 2015	Phase 2
NCT04009772	Assiut University\|Yasser Esmat Mohammed	Emergency Cesarean Section\|Infection Wound	July 1, 2019	Phase 2\|Phase 3
NCT04723472	Shanghai East Hospital	Helicobacter Pylori Infection	August 1, 2023	Not Applicable
NCT03716804	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	Uncomplicated Urinary Tract Infection\|Antibiotic Resistant Infection	June 6, 2018	Phase 4
NCT01524081	The Faculty Hospital Na Bulovce	Acute Appendicitis\|Perforated Gastroduodenal Ulcer\|Small Bowel Obstruction	July 2008	Phase 3
NCT01518192	University Medical Centre Ljubljana\|Slovenian Research Agency	Erythema Migrans\|Post-Lyme Disease Symptoms	June 2006	Phase 4
NCT01659866	Northwestern University	Infection	August 2012	Phase 4
NCT00613769	Halmstad County Hospital	Infection Prophylaxis in Colo Rectal Surgery	September 2007	Phase 4
NCT04161599	Hospital Universitari Vall d′Hebron Research Institute	Wounds and Injuries\|Surgery--Complications	March 1, 2022	Phase 4
NCT04303390	Saud Al Babtain Cardiac Center	Surgical Site Infection	February 6, 2018	Phase 4
NCT04470973	Radboud University Medical Center	Sepsis\|Septic Shock\|Infection, Bacterial\|Critically Ill	July 15, 2020
NCT05398081	Dr. Promise Tamunoipiriala Jaja\|University College Hospital, Ibadan	Surgical Site Infection\|Antibiotics Prophylaxis	December 1, 2021	Phase 2
NCT00497341	Hospital Clinic of Barcelona	Infection	January 2008	Phase 4
NCT05609240	University of Leeds\|University of Birmingham\|Aneurin Bevan University Health Board	Antibiotic Prophylaxis\|Colorectal Surgery	January 1, 2023	Phase 2
NCT03020940	Jiangsu Famous Medical Technology Co., Ltd.	Infectious Disease	January 2017
NCT02850250	Alder Hey Children′s NHS Foundation Trust	Cardiac Event	July 2018
NCT02072798	Odense University Hospital\|University of Copenhagen\|Aase and Ejnar Danielsens Foundation\|Region of Southern Denmark\|University of Southern Denmark	Surgical Wound Infection\|Infection; Cesarean Section\|Complications; Cesarean Section	February 2014	Phase 4
NCT00648726	Pfizer	Pneumonia	January 2003	Phase 3
NCT00730938	Presbyterian Church East Africa Kikuyu Hospital	Cataract\|Endophthalmitis	February 2008	Not Applicable
NCT01237730	National Cheng Kung University	The Patients Who Receive Percutaneous Endoscopic Gastrostomy\|Peristomal Wound Infection After the Operation of PEG\|Prophylactic Antibiotics Before PEG	July 2010	Not Applicable
NCT05337566	Helsinki University Central Hospital\|University of Turku\|Tampere University Hospital\|Kuopio University Hospital\|Oulu University Hospital	Infection Post Op\|Hysterectomy\|Antibiotics\|Prophylactic	September 5, 2022	Not Applicable
NCT05577273	Omri Schwarztuch Gildor\|Clalit Health Services	Urologic Diseases\|Urinary Tract Disease	August 14, 2018	Not Applicable
NCT05388747	Shandong University\|Tianjin Central Hospital of Gynecology Obstetrics	Infectious Disease	May 16, 2022
NCT04378868	Helsinki University Central Hospital	Appendicitis	May 18, 2020	Phase 4
NCT03584919	University Medical Centre Ljubljana	Erythema Chronicum Migrans	June 1, 2006	Not Applicable
NCT02789579	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	Complication of Surgical Procedure	September 2016	Early Phase 1
NCT00000752	National Institute of Allergy and Infectious Diseases (NIAID)\|Adams Laboratories\|Glaxo Wellcome	HIV Infections\|Sinusitis		Phase 2
NCT04616352	Universidad Nacional de Colombia	Urinary Tract Infections	December 26, 2020

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL ( 224.03 mM )

H ₂ O : 50 mg/mL ( 112.01 mM ; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2403 mL	11.2015 mL	22.4029 mL
5 mM	0.4481 mL	2.2403 mL	4.4806 mL
10 mM	0.2240 mL	1.1201 mL	2.2403 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 55 mg/mL (123.22 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Callaghan, et al. Cefuroxime sodium, a New Cephalosporin Antibiotic: Activity in Vitro. Antimicrob Agents Chemother. 1976 Mar;9(3):511-9.
[2] D M Ryan, et al. Cefuroxime sodium, a New Cephalosporin Antibiotic: Activity in Vivo. Antimicrob Agents Chemother. 1976 Mar;9(3):520-5.

Synonyms

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-[[(2Z)-2-(2-furanyl)-2-(methoxyimino)acetyl]amino]-8-oxo-, sodium salt (1:1), (6R,7R)-

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-[[2-furanyl(methoxyimino)acetyl]amino]-8-oxo-, monosodium salt, [6R-[6α,7β(Z)]]-

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-[[(2Z)-2-furanyl(methoxyimino)acetyl]amino]-8-oxo-, monosodium salt, (6R,7R)-

Cefuroxime sodium

640/359

Sodium cefuroxime

Cefuroxime sodium salt

Zinacef

Spectrazol

Kefurox

Kesint

Ipacef

Cefurex

Gibicef

Cefoprim

Cefurin

Novocef

Ultroxim

Curocef

Bioxima

Cefumax

Cefamar

Biociclin

Spectrazole

Duxima

Biofurex

Anaptivan

Lampsporin

Curoxim

Medoxim

一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线